

Payment Amounts for ESRD PPS TDAPA Drugs and Biological Products

Current TDAPA Payment Amounts

Effective October 1, 2026 through December 31, 2026

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.118 (based on ASP pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.003 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.007 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.009 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.122 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.008 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.061 (based on ASP pricing)
J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.068 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.004 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2026, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective July 1, 2026 through September 30, 2026

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.129 (based on ASP pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.003 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.008 (based on ASP pricing)

J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.012 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.121 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.008 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.061 (based on ASP pricing)
J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.075 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.003 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2026, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective April 1, 2026 through June 30, 2026

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$4.741 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.128 (based on ASP pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.003 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.008 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.011 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.157 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.009 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.062 (based on ASP pricing)

J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.086 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.003 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2026, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective January 1, 2026 through March 31, 2026

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$5.635 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.135 (based on ASP pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.003 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.007 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.007 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.159 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.010 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.061 (based on ASP pricing)
J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.086 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.002 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2026, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective October 1, 2025 through December 31, 2025

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$6.046 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.135 (based on ASP pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20mg	\$0.004 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.007 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.011 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.166 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.025 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.060 (based on ASP pricing)
J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.096 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.002 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2025, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective July 1, 2025 through September 30, 2025

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$7.248 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.142 (based on WAC pricing)
Oral-only phosphate binders*			

J0601	Sevelamer carbonate 20 mg	20 mg	\$0.003 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.008 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.004 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.168 (based on ASP pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.021 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.060 (based on WAC pricing)
J0609	Ferric citrate oral 3 mg iron	3 mg	\$0.098 (based on ASP pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.002 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2025, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective April 1, 2025 through June 30, 2025

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on ASP pricing)
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$8.106 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.142 (based on WAC pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.006 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.013 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.009 (based on ASP pricing)

J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.179 (based on WAC pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.016 (based on ASP pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.060 (based on WAC pricing)
J0609	Ferric citrate orl 3 mg iron	3 mg	\$0.111 (based on WAC pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.002 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2025, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective January 1, 2025 through March 31, 2025

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on ASP pricing)
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$8.166 (based on ASP pricing)
J0901	Vadadustat oral 1mg for esrd	1 mg	\$0.142 (based on WAC pricing)
Oral-only phosphate binders*			
J0601	Sevelamer carbonate 20 mg	20 mg	\$0.011 (based on ASP pricing)
J0602	Sevelamer carbonate pdr 20mg	20 mg	\$0.024 (based on ASP pricing)
J0603	Sevelamer hydrochloride 20mg	20 mg	\$0.011 (based on ASP pricing)
J0605	Sucroferric oxyhydroxide 5mg	5 mg	\$0.179 (based on WAC pricing)
J0607	Lanthanum carbonate oral 5mg	5 mg	\$0.017 (based on WAC pricing)
J0608	Lanthanum carbonate pwdr 5mg	5 mg	\$0.060 (based on WAC pricing)

J0609	Ferric citrate orl 3 mg iron	3 mg	\$0.111 (based on WAC pricing)
J0615	Calcium acetate, oral, 23 mg	23 mg	\$0.002 (based on ASP pricing)

*For CY 2025 and 2026, TDAPA for phosphate binders is based on 100 percent of ASP plus an additional amount derived from 6 percent of per-patient phosphate binder spending based on utilization and cost data. For CY 2025, the additional fixed amount of \$36.41 is added to the TDAPA amount for each monthly claim that includes phosphate binders.

Effective October 1, 2024 through December 31, 2024

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on ASP pricing)
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$8.33 (based on WAC pricing)

Effective July 1, 2024 through September 30, 2024

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on ASP pricing)
J0911	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	1.35 mg	\$8.33 (based on WAC pricing)

Effective April 1, 2024 through June 30, 2024

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on WAC pricing)

Effective January 1, 2024 through March 31, 2024

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$ 0.168 (based on ASP pricing)
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on WAC pricing)

Effective October 1, 2023 through December 31, 2023

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
-------	-------------------	-------------------	----------------

J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$ 0.189 (based on ASP pricing)
J0889	Daprodustat, oral, 1 mg, (for ESRD on dialysis)	1 mg	\$3.910 (based on WAC pricing)

Effective July 1, 2023 through September 30, 2023

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$ 0.202*

*Based on ASP pricing

Effective April 1, 2023 through June 30, 2023

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$0.231*

*Based on WAC pricing

Effective January 1, 2023 through March 31, 2023

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$0.222*

*Based on ASP pricing

Effective October 1, 2022 through December 31, 2022

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$0.231*

*Based on WAC pricing

Effective July 1, 2022 through September 30, 2022

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$0.231*

*Based on WAC pricing

Effective April 1, 2022 through June 30, 2022

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0879	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	0.1 microgram	\$0.231*

*Based on WAC pricing

Between January 1, 2021 and March 31, 2022 there were no new renal dialysis drugs or biological products eligible for the TDAPA.

Prior TDAPA Payment Amounts

Effective October 1, 2020 through December 31, 2020

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.085
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.023

Effective July 1, 2020 through September 30, 2020

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.158
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.117

Effective April 1, 2020 through June 30, 2020

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.231
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.200

Effective January 1, 2020 through March 31, 2020

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.446
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.308

Effective October 1, 2019 through December 31, 2019

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.765
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.602

Effective July 1, 2019 through September 30, 2019

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.765
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.680

Effective April 1, 2019 through June 30, 2019

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.807
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.825

Effective January 1, 2019 through March 31, 2019

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.838

J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.879
-------	----------------------------	--------	---------

Effective October 1, 2018 through December 31, 2018

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.867
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$2.983

Effective July 1, 2018 through September 30, 2018

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.898
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$3.171

Effective April 1, 2018 through June 30, 2018

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.908
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$3.466

Effective January 1, 2018 through March 31, 2018

HCPCS	Short Description	HCPCS Code Dosage	Payment Amount
J0604	oral cinacalcet esrd dialysi	1 MG	\$0.909
J0606	inj., etelcalcetide 0.1 mg	0.1 MG	\$3.466